BreezeBio (formerly Genedit) closed a $60 million financing to shift from an open delivery platform to building an internal pipeline anchored by its Nanogalaxy delivery technology. The round funds clinical‑enabling work for the company’s lead programs, including an mRNA‑based candidate aimed at inducing tolerance in Type 1 diabetes and additional internal therapeutics. The financing and rebrand reflect a broader industry pattern of delivery‑focused startups moving toward proprietary programs to capture downstream value. BreezeBio said proceeds will support IND‑enabling studies and expansion of its delivery platform capabilities.